Distribution of CCR5delta32 in human immunodeficiency virus-infected children and its relationship to disease course. NLM AIDSLINE Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Distribution of CCR5delta32 in human immunodeficiency virus-infected children and its relationship to disease course.

Clin Diagn Lab Immunol. 1998 Jan;5(1):38-40. Unique Identifier : AIDSLINE MED/98115412
Bakshi SS; Zhang L; Ho D; Than S; Pahwa SG; Department of Pediatrics, North Shore University Hospital-New York; University School of Medicine, Manhasset, USA.

Abstract: Homozygosity for a 32-bp deletion in the CCR5 gene (CCR5delta32) has been shown to confer resistance to infection with the macrophage-tropic strain of human immunodeficiency virus (HIV) type 1. We examined the distribution of CCR5delta32 in 47 children (age range, 1.5 to 19 years), of whom 43 were infected with HIV, by the perinatal route (n = 41) or by the intravenous route (n = 2). The infected patients were classified as rapid progressors (RP) (n = 7) (CDC category C3 or death by 2 years of age), non-rapid progressors (NRP) (n = 17) (survival for > or =8 years after infection), or intermediate (n = 19). CCR5delta32 heterozygosity was found in two HIV-infected children, both NRP. None of the subjects were homozygous for CCR5delta32, and the remaining children had no evidence of CCR5delta32. The presence of CCR5delta32 heterozygosity in 4.8% of this, predominantly non-Caucasian population is consistent with the published distribution of the mutation. The finding that CCR5delta32 was present only in NRP and not in any RP is in agreement with previous reports suggesting that heterozygosity for CCR5delta32 may confer limited protection from disease progression.
Keywords: *HIV Infections/GENETICS *Receptors, Chemokine/GENETICSKWDhivinfections/geneticsKWDreceptors,chemokine/genetics
980630
M9861799

Copyright © 1998 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .